DUBLIN – Shares in Poxel SA opened Thursday at €10.22 (US$11.21) on the Euronext exchange in Paris, up 56 percent on the previous close, in response to positive top-line data from a phase IIb trial in Japan of imeglimin in 299 patients with type 2 diabetes.